Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
2.
Minerva Med ; 101(4): 215-38, 2010 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21030935

RESUMEN

Platelet activation and thrombin formation are integral in the pathophysiology of acute coronary syndrome. Currently available pharmacotherapies inhibit the cascade of platelet aggregation and activation, and prevent thrombin formation to limit platelet-fibrin complex formation, thus maintaining coronary patency and ultimately improving clinical outcomes. This is a rapidly evolving field with next-generation antithrombotic combinations aimed at achieving the "Holy Grail" of improved anti-ischemic efficacy whilst minimizing bleeding risk. Our review article focuses on the use of antithrombotic agents for the contemporary management of patients with ACS.


Asunto(s)
Síndrome Coronario Agudo/tratamiento farmacológico , Fibrinolíticos/uso terapéutico , Inhibidores de Agregación Plaquetaria/uso terapéutico , Anticoagulantes/uso terapéutico , Humanos , Activación Plaquetaria , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/antagonistas & inhibidores , Antagonistas del Receptor Purinérgico P2Y/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA